• Profile

Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy

HPB Dec 22, 2021

Landa K, Schmitz R, Farrow NE, et al. - In resectable pancreatic cancer, a superior long-term survival is conferred by surgical resection (SR) than multiagent chemotherapy (MCT).

  • This study included patients from the NCDB (2013-2015) with stage I-IIb pancreatic head adenocarcinoma who received either MCT or SR [3,103 patients underwent MCT alone (60.3%) and 2,043 received SR alone (39.7%)].

  • SR was shown to have an overall survival (OS) disadvantage at 30 (HR 3.99) and 60 days (HR 1.85), but an OS benefit following 90 days (HR 0.59).

  • A landmark analysis conditioned on 90 days survival after treatment commencement revealed improved median OS for SR (17.0 vs 12.2 months); 3-year OS improved by 21.3% with SR, despite older age of patients (median 72 vs 67 years) and higher Charlson-Deyo comorbidity scores (≥2: 11.2 vs 8.6%).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen